National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- (-) Cancer (6)
- Chronic Conditions (1)
- Clinician-Patient Communication (1)
- Communication (1)
- Comparative Effectiveness (1)
- Elderly (3)
- (-) Healthcare Costs (6)
- Healthcare Delivery (1)
- Infectious Diseases (1)
- Medicare (3)
- Medication (3)
- Outcomes (1)
- Patient-Centered Healthcare (1)
- Patient and Family Engagement (1)
- Sexual Health (1)
- Vaccination (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedChen Y, Lairson DR, Chan W
Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. payer's perspective.
The researchers sought to determine the cost-effectiveness (measured as cost per life-year saved) of front-line novel agent-based therapy use among a cohort of elderly patients with multiple myeloma (MM) in a real-world setting. They concluded that, given the most common treatment practices in the United States, the use of novel agent-based therapy is not cost-effective at its current level of cost and effectiveness.
AHRQ-funded; HS018956.
Citation: Chen Y, Lairson DR, Chan W .
Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a U.S. payer's perspective.
J Manag Care Spec Pharm 2017 Aug;23(8):831-43. doi: 10.18553/jmcp.2017.23.8.831.
.
.
Keywords: Healthcare Costs, Cancer, Comparative Effectiveness, Healthcare Costs, Medication
Shih YT, Xu Y, Liu L
Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries.
This study examined trends in targeted oral anticancer medication (TOAM) prices and patient out-of-pocket (OOP) payments in Medicare Part D and estimated the actual effects on patient OOP payments of partial filling of the coverage gap by 2012. It concluded that rising TOAM prices threaten the financial relief patients have begun to experience under closure of the coverage gap in Medicare Part D.
AHRQ-funded; HS020263.
Citation: Shih YT, Xu Y, Liu L .
Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries.
J Clin Oncol 2017 Aug 1;35(22):2482-89. doi: 10.1200/jco.2017.72.3742.
.
.
Keywords: Cancer, Medication, Healthcare Costs, Medicare, Elderly
Rocque GB, Pisu M, Jackson BE
Resource use and Medicare costs during lay navigation for geriatric patients with cancer.
This study examined the influence of lay navigation on health care spending and resource use among geriatric patients with cancer within The University of Alabama at Birmingham Health System Cancer Community Network. It found that, compared with a matched comparison group, the mean total costs declined by $781.29 more per quarter per navigated patient, for an estimated $19 million decline per year across the network.
AHRQ-funded; HS023009.
Citation: Rocque GB, Pisu M, Jackson BE .
Resource use and Medicare costs during lay navigation for geriatric patients with cancer.
JAMA Oncol 2017 Jun;3(6):817-25. doi: 10.1001/jamaoncol.2016.6307.
.
.
Keywords: Elderly, Cancer, Healthcare Costs, Medicare, Patient and Family Engagement, Patient-Centered Healthcare, Healthcare Delivery
Shih YT, Chien CR
A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment.
This review identified 15 articles that covered 3 topics related to patient-physician cost communication: patient attitude, physician acceptance, and the associated outcomes. The data suggested that cost communication was associated with improved patient satisfaction, lower out-of-pocket expenses, and a higher likelihood of medication nonadherence; none of the studies established causality.
AHRQ-funded; HS020263.
Citation: Shih YT, Chien CR .
A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment.
Cancer 2017 May 15;123(6):928-39. doi: 10.1002/cncr.30423.
.
.
Keywords: Cancer, Communication, Healthcare Costs, Outcomes, Clinician-Patient Communication
Haidari LA, Brown ST, Constenla D
Geospatial planning and the resulting economic impact of human papillomavirus vaccine introduction in Mozambique.
Researchers developed the Strategic Integrated Geo-temporal Mapping Application) to determine the potential economic impact of HPV immunization in Mozambique. If each health center covers a catchment area with a 5-km radius, then 40 percent of the target population could be reached to prevent 50 cases, 178 disability-adjusted life years, and US $202,854 in health care costs and lost productivity.
AHRQ-funded; HS023317.
Citation: Haidari LA, Brown ST, Constenla D .
Geospatial planning and the resulting economic impact of human papillomavirus vaccine introduction in Mozambique.
Sex Transm Dis 2017 Apr;44(4):222-26. doi: 10.1097/olq.0000000000000574.
.
.
Keywords: Cancer, Healthcare Costs, Infectious Diseases, Sexual Health, Vaccination
Shen C, Zhao B, Liu L
Financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications.
In this study, the investigators examined financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications. The authors concluded that patients experience quick entry and exit from the coverage gap (also called the donut hole) as a result of the high price of targeted oral anticancer medications. They suggested that closing the donut hole would provide financial relief during the initial month(s) of treatment but will not completely eliminate the financial burden.
AHRQ-funded; HS020263.
Citation: Shen C, Zhao B, Liu L .
Financial burden for patients with chronic myeloid leukemia enrolled in Medicare Part D taking targeted oral anticancer medications.
J Oncol Pract 2017 Feb;13(2):e152-e62. doi: 10.1200/JOP.2016.014639..
Keywords: Cancer, Chronic Conditions, Elderly, Healthcare Costs, Medicare, Medication